SCR7

• Description:

  SCR7 is an unstable form that can be autocyclized into a stable form SCR7 pyrazine (HY-107845) . SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine increases the efficiency of Cas9-mediated homology-directed repair (HDR) . SCR7 pyrazine induces cell apoptosis and has anticancer activity[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Apoptosis; CRISPR/Cas9; DNA/RNA Synthesis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/SCR7.html

• Purity:

  98.22

• Solubility:

  DMSO : ≥ 45 mg/mL

• Smiles:

  O=C(N1)C(/N=C/C2=CC=CC=C2)=C(NC1=S)/N=C/C3=CC=CC=C3

• Molecular Formula:

  C18H14N4OS

• Molecular Weight:

  334.39

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Srivastava M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012 Dec 21;151 (7) :1474-87.|[2]Lin C, et al. Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells. Sci Rep. 2016 Oct 7;6:34531.|[3]Supriya V Vartak, et al. Autocyclized and Oxidized Forms of SCR7 Induce Cancer Cell Death by Inhibiting Nonhomologous DNA End Joining in a Ligase IV Dependent Manner. FEBS J. 2018 Nov;285 (21) :3959-3976.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Citation 01:

  BMC Biotechnol. 2021 Jul 27;21 (1) :45.|Cell Death Discov. 2025 Aug 23;11 (1) :402.|EMBO Rep. 2019 Mar;20 (3) :e46821.|J Genet Genomics. 2021 Feb 20;48 (2) :134-146.|J Immunol. 2020 Apr 1;204 (7) :1904-1918.|J Immunother Cancer. 2022 Jan;10 (1) :e003809.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Mol Ther Nucleic Acids. 2024 Jul 17;35 (3) :102274.|Onco Targets Ther. 2018 Aug 17:11:4945-4953.|Sens Actuators B Chem. 19 February 2022, 131598.|Stem Cell Res Ther. 2024 Dec 2;15 (1) :458.|Viruses. 2023 Nov 14;15 (11) :2256.|Int J Mol Sci. 2022 Jul 7;23 (14) :7518.|Int J Mol Sci. 2025 May 3;26 (9) :4361.|Nat Commun. 2025 Jul 15;16 (1) :6502.|Sci Adv. 2025 Jul 11;11 (28) :eadw1720.|Trends Biotechnol. 2025 Aug 30:S0167-7799 (25) 00314-2.|Trends Biotechnol. 2025 Jul;43 (7) :1743-1764.|University of Georgia. 2025.|Virology. 2025 May:606:110504.

• CAS Number:

  [1533426-72-0]